memantine has been researched along with Cranial Nerve II Diseases in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 7.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 7.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value." | 3.73 | Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "To determine, using electrophysiological measures of visual system function, whether oral daily dosing of memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. ( Chun, T; Hare, WA; Lai, RK; Ruiz, G; Ton, H; Wheeler, L; WoldeMussie, E, 2004) |
| "To determine, using anatomic measurements, whether daily oral dosing with memantine is both safe and effective to reduce the injury associated with experimental glaucoma in primates." | 3.72 | Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. ( Feldmann, B; Hare, WA; Ruiz, G; Ton, H; Weinreb, RN; Wheeler, L; Wijono, M; WoldeMussie, E; Zangwill, L, 2004) |
| "Glaucoma is a neurodegenerative disease for which the neuropathic pathology has been studied since 1972." | 2.44 | History of neuroprotection and rationale as a therapy for glaucoma. ( Levin, LA; Peeples, P, 2008) |
| "Pre-treatment with tacrolimus markedly protected RGC-5 cells from NMDA-induced neurotoxicity, and then both spontaneous RGC death and degenerative changes to the optic nerve in p50-deficient mice were significantly reduced by the chronic administration of tacrolimus." | 1.37 | Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation. ( Hayashi, T; Murata, T; Nakamura-Yanagidaira, T; Sano, K; Takahashi, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinreb, RN | 3 |
| Liebmann, JM | 1 |
| Cioffi, GA | 1 |
| Goldberg, I | 1 |
| Brandt, JD | 1 |
| Johnson, CA | 1 |
| Zangwill, LM | 1 |
| Schneider, S | 1 |
| Badger, H | 1 |
| Bejanian, M | 1 |
| Danesh-Meyer, HV | 1 |
| Levin, LA | 2 |
| Nakamura-Yanagidaira, T | 1 |
| Takahashi, Y | 1 |
| Sano, K | 1 |
| Murata, T | 1 |
| Hayashi, T | 1 |
| Hare, WA | 2 |
| WoldeMussie, E | 2 |
| Lai, RK | 1 |
| Ton, H | 2 |
| Ruiz, G | 2 |
| Chun, T | 1 |
| Wheeler, L | 2 |
| Wijono, M | 1 |
| Feldmann, B | 1 |
| Zangwill, L | 1 |
| Yücel, YH | 1 |
| Gupta, N | 1 |
| Zhang, Q | 1 |
| Mizisin, AP | 1 |
| Kalichman, MW | 1 |
| Zhong, L | 1 |
| Bradley, J | 1 |
| Schubert, W | 1 |
| Ahmed, E | 1 |
| Adamis, AP | 1 |
| Shima, DT | 1 |
| Robinson, GS | 1 |
| Ng, YS | 1 |
| Kusari, J | 1 |
| Zhou, S | 1 |
| Padillo, E | 1 |
| Clarke, KG | 1 |
| Gil, DW | 1 |
| Peeples, P | 1 |
| Naskar, R | 1 |
| Vorwerk, CK | 1 |
| Dreyer, EB | 1 |
| Pop, E | 1 |
3 reviews available for memantine and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Neuroprotection: extrapolating from neurologic diseases to the eye.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Endpoint Determination; Excitatory Amino | 2009 |
History of neuroprotection and rationale as a therapy for glaucoma.
Topics: Disease Progression; Glaucoma; Humans; Memantine; Neurodegenerative Diseases; Neuroprotective Agents | 2008 |
Saving the nerve from glaucoma: memantine to caspaces.
Topics: Animals; Apoptosis; Caspase Inhibitors; Caspases; Excitatory Amino Acid Antagonists; Glaucoma; Gluta | 1999 |
1 trial available for memantine and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind | 2018 |
7 other studies available for memantine and Cranial Nerve II Diseases
| Article | Year |
|---|---|
Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Calcineurin; Genes, Reporter; Hum | 2011 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.
Topics: Administration, Oral; Animals; Cell Count; Chronic Disease; Disease Models, Animal; Electroretinogra | 2004 |
Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.
Topics: Administration, Oral; Animals; Cell Count; Cell Survival; Disease Models, Animal; Excitatory Amino A | 2004 |
Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma.
Topics: Animals; Atrophy; Cell Count; Cytoprotection; Disease Models, Animal; Excitatory Amino Acid Antagoni | 2006 |
Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
Topics: Animals; Axons; Cell Survival; Disease Models, Animal; Erythropoietin; Fluorescent Antibody Techniqu | 2007 |
Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood-Retinal Barrier; Body Weight; Cell Count; Coloring Agents; Diabetes Me | 2007 |
Trends in neuroprotection.
Topics: Aged; Amlodipine; Animals; Antiparkinson Agents; Apoptosis; Brain Diseases; Calcium Channel Blockers | 2002 |